-
1
المؤلفون: Koichi Goto, Mitsuhiro Takenoyama, Koji Takeda, Shinji Atagi, Hidehito Horinouchi, M. Nishio, Tomohide Tamura, Naoyuki Nogami, Kazuhiko Nakagawa, Tomonori Hirashima, Hideo Saka, Naoki Sumiyoshi, Hiroshi Isobe, Hiroshi Sakai, Miyako Satouchi, Toyoaki Hida, Toshiaki Takahashi, Hiroshi Tanaka, Koichi Minato, Makoto Maemondo, Nobuyuki Katakami
المصدر: Cancer Medicine
Cancer Medicine, Vol 8, Iss 11, Pp 5183-5193 (2019)مصطلحات موضوعية: 0301 basic medicine, Male, Cancer Research, Lung Neoplasms, non-small cell lung cancer (NSCLC), Phases of clinical research, Kaplan-Meier Estimate, Gastroenterology, 0302 clinical medicine, Antineoplastic Agents, Immunological, Japan, Carcinoma, Non-Small-Cell Lung, Molecular Targeted Therapy, Neoplasm Metastasis, Original Research, Aged, 80 and over, Standard treatment, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Treatment Outcome, Oncology, Docetaxel, 030220 oncology & carcinogenesis, Toxicity, Female, Nivolumab, phase II study, medicine.drug, Adult, medicine.medical_specialty, lcsh:RC254-282, 03 medical and health sciences, Clinical Trials, Phase II as Topic, Internal medicine, medicine, Biomarkers, Tumor, non‐small cell lung cancer (NSCLC), Humans, Radiology, Nuclear Medicine and imaging, Lung cancer, programmed cell death 1 ligand 1 (PD‐L1), Aged, Neoplasm Staging, nivolumab, business.industry, Clinical Cancer Research, medicine.disease, Discontinuation, 030104 developmental biology, programmed cell death 1 receptor (PD‐1), business
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d0254674afd607d2a94e714630a3d09Test
http://europepmc.org/articles/PMC6718542Test -
2
المؤلفون: Kiyohiko Hatake, Masafumi Taniwaki, Noriko Fukuhara, Kiyoshi Ando, Dai Maruyama, Tsutomu Kobayashi, Yasunobu Abe, Ilseung Choi, Tomohiro Kinoshita, Yukari Shirasugi, Yusuke Higuchi, Kensei Tobinai, Yasushi Onishi, Yasuhito Terui
المصدر: Cancer Science
مصطلحات موضوعية: 0301 basic medicine, Male, Cancer Research, Immunoconjugates, Programmed Cell Death 1 Receptor, Phases of clinical research, Gastroenterology, 0302 clinical medicine, Clinical endpoint, Brentuximab vedotin, programmed death‐1, Aged, 80 and over, Brentuximab Vedotin, Remission Induction, Antibodies, Monoclonal, General Medicine, Middle Aged, Rash, Hodgkin Disease, Oncology, 030220 oncology & carcinogenesis, Original Article, Female, immunotherapy, medicine.symptom, Nivolumab, medicine.drug, Adult, medicine.medical_specialty, Malignancy, Disease-Free Survival, 03 medical and health sciences, Refractory, Asian People, Clinical Research, Internal medicine, medicine, Humans, Adverse effect, Aged, nivolumab, business.industry, Original Articles, medicine.disease, Surgery, 030104 developmental biology, Japanese, Neoplasm Recurrence, Local, business, Hodgkin lymphoma
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b65c361bb1ba8c5e7b6f7237c88eed4Test
http://europepmc.org/articles/PMC5448600Test -
3
المؤلفون: Mark G. Qian, Gerald Steven Falchook, Neeraj Gupta, Robin E. Norris, Huyuan Yang, John Nemunaitis, Richard Labotka, Michael J. Hanley, Karthik Venkatakrishnan, Siqing Fu, Raymond P. Perez
المصدر: British Journal of Clinical Pharmacology
مصطلحات موضوعية: 0301 basic medicine, Adult, Boron Compounds, Male, medicine.medical_specialty, ixazomib, hepatic impairment, phase 1 clinical trial, Glycine, Phases of clinical research, Administration, Oral, Gastroenterology, Ixazomib, 03 medical and health sciences, chemistry.chemical_compound, Young Adult, 0302 clinical medicine, Pharmacokinetics, Internal medicine, Neoplasms, medicine, Humans, Pharmacology (medical), Adverse effect, solid tumours, Aged, Pharmacology, Aged, 80 and over, business.industry, proteasome inhibitor, Hepatic impairment, Liver Diseases, Middle Aged, Blood proteins, Confidence interval, Surgery, 030104 developmental biology, chemistry, 030220 oncology & carcinogenesis, Proteasome inhibitor, Female, business, Proteasome Inhibitors, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5db9f258ce89891d53fb094e7872859Test
http://europepmc.org/articles/PMC5089614Test